Skip to content

Incidence of low pressure in the weaning of vasopressor drugs

Incidence of hipotension in the weaning of vasopressor drugs

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-10smbw65
Enrollment
Unknown
Registered
2022-08-23
Start date
2022-05-18
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septicemia not specified

Interventions

This is a randomized, open-label, two-arm clinical trial. Randomization through opaque, sealed and numbered envelopes. Sample selection for convenience. A total of 78 patients, 39 of which were alloca
D12.644.400.900
D02.092.063.480

Sponsors

Hospital Nossa Senhora da Conceição
Lead Sponsor
Hospital Nossa Senhora da Conceição
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients; both genders; older than 18 years; hospitalized for septic shock; in use of noradrenaline and vasopressin associated

Exclusion criteria

Exclusion criteria: Patients in whom the reduction of these vasopressors (noradrenaline and vasopressin) is related to the introduction of adrenaline or is related to the process of withdrawal of therapeutic support (therapeutic limitation)

Design outcomes

Primary

MeasureTime frame
The incidence of hypotension will be evaluated in the first 24 hours after the beginning of the reduction of one of the vasoactive drugs (noradrenaline or vasopressin), through medical records and prescriptions. Hypotension is defined as a fall in mean arterial pressure below 65 mmHg, triggering one or more of the following measures: a) administration of an aliquot of crystalloid or colloid, b) increase in the dose of the remaining vasoactive drug, or c) reinstitution of the vasoactive drug paused.

Secondary

MeasureTime frame
Patients' mortality will be evaluated in a 28-day follow-up.;The time (in days) of hospitalization in the Intensive Care Unit will be evaluated.;To quantify the time in use of vasoactive drugs, after the reduction of the first drug (noradrenaline or vasopressin), in days, in a follow-up of up to seven days. The use of vasoactive drugs is understood to mean the use of any vasopressor drug. Interruption means suspension for at least 24 hours.;To quantify the incidence of arrhythmias with hemodynamic repercussions, in the first 24 hours after the reduction of the first drug (noradrenaline or vasopressin). Events in which hemodynamic worsening required electrical or chemical cardioversion are included in this group.;To quantify the incidence of patients on hemodialysis, whether intermittent or continuous, in the first 72 hours after the reduction of the first drug (noradrenaline or vasopressin). Chronic dialysis patients are excluded from this analysis.

Countries

Brazil

Contacts

Public ContactUnidade de Terapia Intensiva GHC

Hospital Nossa Senhora da Conceição

casmallmann@yahoo.com.br55 (51) 3357-2000

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026